News
Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.
Zacks Investment Research on MSN23h
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform WellSwiss pharma giant Roche Holding AG (RHHBY) reported sales of CHF 30.9 billion for the first half of 2025, up 4% year over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback